

wherein said composition exhibits anti-infectious and hematopoietic properties. --

Cancel claim 21 without prejudice.

Amend claim 22 as follows:

22. (amended) The cell composition according to claim 20, wherein said progenitor cells are present in an amount of about 0.1 to about 20%, said percentage being expressed with respect to the total number of cells. --

Cancel claims 24 and 25 without prejudice.

Amend claim 26 as follows:

26. (amended) The cell composition according to claim 20, wherein said progenitor cells contain from about 0.1 to about 20% of stem cells, expressed with respect to the total number of progenitor cells. --

Cancel claims 29-31 without prejudice.

Add the following new claims:

34. (new) A composition comprising, a pharmaceutically acceptable carrier and as an active substance, the cell composition according to claim 22.

35. (new) A composition comprising, a pharmaceutically acceptable carrier and as an active substance, the cell composition according to claim 23.

--36. (new) A composition comprising, a pharmaceutically acceptable carrier and as an active substance, the cell composition according to claim 26.

--37 (new) The cell composition according to claim 22, wherein said composition is derived from and/or included in a peripheral blood mononuclear cell composition containing:

- from about 10 to about 50% of monocytes,
- from about 10 to about 70% of lymphocytes,
- from about 0.1 to about 20% of progenitor cells,
- from about 1 to about 50% of polynuclear cells, and
- from about 0.1 to about 20% of stem cells.

--38. (new) The cell composition according to claim 23, wherein said composition is derived from and/or included in a peripheral blood mononuclear cell composition containing:

- from about 10 to about 50% of monocytes,
- from about 10 to about 70% of lymphocytes,
- from about 0.1 to about 20% of progenitor cells,
- from about 1 to about 50% of polynuclear cells, and
- from about 0.1 to about 20% of stem cells.

--39. (new) The cell composition according to claim 26, wherein said composition is derived from and/or included in a peripheral blood mononuclear cell composition containing:

- from about 10 to about 50% of monocytes,
- from about 10 to about 70% of lymphocytes,